|
|
Post by ktim on Feb 7, 2020 12:36:12 GMT -5
Think I'd be happy with MNKD turning into a boring investment. Excitement is overrated when it comes to stocks.
|
|
|
|
Post by harryx1 on Feb 11, 2020 11:57:50 GMT -5
Why isn't VDEX doing seminars like this showcasing their successes with different patients (T1D & T2D)... Explain what Afrezza is. Explain how it's different. Show how effective it can be when used properly. Show what meds a patient was on Show what their A1c was coming in Show how fast A1c dropped Show what meds patient dropped Show, show, show.... tcoyd.org/wp-content/uploads/2020/02/TCOYD-CME-Belleve20-SlideDeck.pdf   |
|
|
|
Post by longliner on Feb 11, 2020 12:06:48 GMT -5
Why isn't VDEX doing seminars like this showcasing their successes with different patients (T1D & T2D)... Explain what Afrezza is. Explain how it's different. Show how effective it can be when used properly. Show what meds a patient was on Show what their A1c was coming in Show how fast A1c dropped Show what meds patient dropped Show, show, show.... tcoyd.org/wp-content/uploads/2020/02/TCOYD-CME-Belleve20-SlideDeck.pdf Maybe they first have to have patients to showcase? Who would know? |
|
|
|
Post by goyocafe on Feb 11, 2020 12:10:19 GMT -5
Why isn't VDEX doing seminars like this showcasing their successes with different patients (T1D & T2D)... Explain what Afrezza is. Explain how it's different. Show how effective it can be when used properly. Show what meds a patient was on Show what their A1c was coming in Show how fast A1c dropped Show what meds patient dropped Show, show, show.... tcoyd.org/wp-content/uploads/2020/02/TCOYD-CME-Belleve20-SlideDeck.pdfWhy aren’t organizations like TCOYD advocating Afrezza? It seems much simpler than the treatment program this patient ended up on. Metformin, SFU, dpp4-inhibitor, SGLT-2i, and a continuing list that included GLP-1 and basal insulin at bedtime. Wouldn’t VDEX recommend dumping all of it for Afrezza? Seems like an easy thing to sell the patient on, too. |
|
|
|
Post by mango on Feb 11, 2020 12:12:51 GMT -5
Why isn't VDEX doing seminars like this showcasing their successes with different patients (T1D & T2D)... Explain what Afrezza is. Explain how it's different. Show how effective it can be when used properly. Show what meds a patient was on Show what their A1c was coming in Show how fast A1c dropped Show what meds patient dropped Show, show, show.... tcoyd.org/wp-content/uploads/2020/02/TCOYD-CME-Belleve20-SlideDeck.pdfI've often wondered the same thing. Also, I have suggested to VDex for a couple years now that they collect real-world patient data on their patients to use as leverage with FDA label changes and pubs. I don't understand why they don't get out there and talk with the local communities and do presentations and spread the word, grow awareness and patient base. |
|
|
|
Post by brentie on Feb 11, 2020 12:20:43 GMT -5
"Why aren’t organizations like TCOYD advocating Afrezza? It seems much simpler than the treatment program this patient ended up on. Metformin, SFU, dpp4-inhibitor, SGLT-2i, and a continuing list that included GLP-1 and basal insulin at bedtime.
Wouldn’t VDEX recommend dumping all of it for Afrezza? Seems like an easy thing to sell the patient on, too."
-------------------------------------------------------------------------------------------
Good question, Goyo.
|
|
|
|
Post by agedhippie on Feb 11, 2020 12:26:50 GMT -5
Why aren’t organizations like TCOYD advocating Afrezza? It seems much simpler than the treatment program this patient ended up on. Metformin, SFU, dpp4-inhibitor, SGLT-2i, and a continuing list that included GLP-1 and basal insulin at bedtime. Wouldn’t VDEX recommend dumping all of it for Afrezza? Seems like an easy thing to sell the patient on, too. VDEX would say dump it all and go with Afrezza. The SoC would not say that at all though and that's what these guides follow. Importantly she was happy with the result. |
|
|
|
Post by goyocafe on Feb 11, 2020 12:32:46 GMT -5
Why aren’t organizations like TCOYD advocating Afrezza? It seems much simpler than the treatment program this patient ended up on. Metformin, SFU, dpp4-inhibitor, SGLT-2i, and a continuing list that included GLP-1 and basal insulin at bedtime. Wouldn’t VDEX recommend dumping all of it for Afrezza? Seems like an easy thing to sell the patient on, too. VDEX would say dump it all and go with Afrezza. The SoC would not say that at all though and that's what these guides follow. Importantly she was happy with the result. Understood, and expected response. She also probably doesn’t know how much simpler her life could be. But that’s where Mannkind’s marketing fails to deliver. Yep, the SOC, the label, hindsight would have made it obvious the day the label came out for Afrezza that this was going to be nearly impossible odds. |
|
|
|
Post by mango on Feb 11, 2020 12:35:18 GMT -5
Why aren’t organizations like TCOYD advocating Afrezza? It seems much simpler than the treatment program this patient ended up on. Metformin, SFU, dpp4-inhibitor, SGLT-2i, and a continuing list that included GLP-1 and basal insulin at bedtime. Wouldn’t VDEX recommend dumping all of it for Afrezza? Seems like an easy thing to sell the patient on, too. VDEX would say dump it all and go with Afrezza. The SoC would not say that at all though and that's what these guides follow. Importantly she was happy with the result. The SoC also doesn't rec patients to administer Cannabis-based medical preperations for their conditions, but many, many physicians prescribe and advocate for Cannabis medicine. One of the main reasons for many new physicians coming on board, and for strengthening the movement is because of grass roots marketing (local presentations on the community level by physicians with patient cases presented). Why doesn't, or better yet, why HASN't, VDex spreadheaded this effort for Afrezza? They have an entire SAB, for what? They should be out there presenting their patient data to the community and physicians and professionals at conferences and universities, etc...INSTEAD of making youtube videos bashing MannKind management. |
|
|
|
Post by agedhippie on Feb 11, 2020 13:08:49 GMT -5
... Why doesn't, or better yet, why hasn't, VDex spearheaded this effort for Afrezza? They have an entire SAB, for what? They should be out there presenting their patient data to the community and physicians and professionals at conferences and universities, etc...INSTEAD of making youtube videos bashing MannKind management. Perhaps Mannkind's management would get bashed less if they did more of the work you suggest VDEX should be doing for free. Selling Afrezza is Mannkind's job, treat diabetics is what VDEX does. It's not the same thing. A SAB, any company's SAB, is there to advise the company on what they should be doing scientifically. They are not there to perform marketing, not least because that's not where their abilities lie. |
|
|
|
Post by mango on Feb 11, 2020 13:23:53 GMT -5
... Why doesn't, or better yet, why hasn't, VDex spearheaded this effort for Afrezza? They have an entire SAB, for what? They should be out there presenting their patient data to the community and physicians and professionals at conferences and universities, etc...INSTEAD of making youtube videos bashing MannKind management. Perhaps Mannkind's management would get bashed less if they did more of the work you suggest VDEX should be doing for free. Selling Afrezza is Mannkind's job, treat diabetics is what VDEX does. It's not the same thing. A SAB, any company's SAB, is there to advise the company on what they should be doing scientifically. They are not there to perform marketing, not least because that's not where their abilities lie. Expected response. I stand by what I said. BTW—you're not even invested in MannKind. |
|
|
|
Post by longliner on Feb 11, 2020 13:37:49 GMT -5
Perhaps Mannkind's management would get bashed less if they did more of the work you suggest VDEX should be doing for free. Selling Afrezza is Mannkind's job, treat diabetics is what VDEX does. It's not the same thing. A SAB, any company's SAB, is there to advise the company on what they should be doing scientifically. They are not there to perform marketing, not least because that's not where their abilities lie. Expected response. I stand by what I said. BTW—you're not even invested in MannKind. Dang it Mango...he doesn't have to be invested in Mannkind to bash them, in fact it wouldn't make any sense to bash his own investment. He would just sell and move on.🤭 |
|
|
|
Post by brotherm1 on Feb 11, 2020 13:48:53 GMT -5
Perhaps Mannkind's management would get bashed less if they did more of the work you suggest VDEX should be doing for free. Selling Afrezza is Mannkind's job, treat diabetics is what VDEX does. It's not the same thing. A SAB, any company's SAB, is there to advise the company on what they should be doing scientifically. They are not there to perform marketing, not least because that's not where their abilities lie. Expected response. I stand by what I said. BTW—you're not even invested in MannKind. The fact he’s not invested in MNKD is just another indication he’s much smarter than those of us that are. |
|
|
|
Post by mango on Feb 11, 2020 13:54:01 GMT -5
Expected response. I stand by what I said. BTW—you're not even invested in MannKind. The fact he’s not invested in MNKD is just another indication he’s much smarter than those of us that are. Maybe for you, but that definitely does not align with my thinking since I believe the company has a very bright future, and generally disagree with everything (except on some things) aged has to say concerning Afrezza and MannKind. 😉 |
|
|
|
Post by brotherm1 on Feb 11, 2020 14:16:38 GMT -5
Well they better get their brights on soon because if this extraordinary ten year long bull market and the economy soon tanks, our little struggling MNKD’s shares will be sold and shorted in oblivion. IMO
|
|
